{
  "id": 17872632,
  "title": "BWXT Q3 2026 slides: margins expand despite revenue miss",
  "url": "https://urgent.news/2026/11/02/bwxt-q3-2026-slides-margins-expand-despite-revenue-miss",
  "topic": "culture",
  "section": "Culture",
  "published": "2026-11-02T23:19:15.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/bwxt-q3-2026-slides-margins-expand-despite-revenue-miss-93CH-4993192"
  },
  "original_language": "en",
  "account": "On November 2, 2026, BWXT Technologies (NYSE: BWXT) released its Q3 2026 earnings report, showcasing robust financial performance despite missing revenue projections. The company's shares experienced a 2.66% drop to $127 in post-market trading. While adjusted earnings surpassed market expectations, revenue came in slightly below forecasts. This disparity illustrates the company's operational excellence amid heightened investor expectations for growth in defense programs and commercial nuclear markets. BWXT's third-quarter performance demonstrated broad-based expansion, with revenue growing 10% year-over-year to $953 million, though 1.8% below the $970.42 million consensus estimate. Adjusted EBITDA increased by 19% to $180 million, yielding an 18.9% margin, a 150 basis point improvement from the previous year. Non-GAAP earnings per share rose 26% to $1.26, toppling the $1.18 consensus by $0.08. Free cash flow surged by 59% to $151 million, underscoring improved working capital management and profitability. Capital expenditures accounted for 5.0% of revenue as the firm invested in manufacturing capacity expansion. The company's segment-level performance revealed diverging growth patterns: government operations grew 4% to $639 million, marginally expanding adjusted EBITDA by 22% to $144 million. Commercial operations, however, surged 25% to $314 million, propelled by acquisitions and organic growth in nuclear power components and medical products. BWXT adjusted its 2026 guidance, projecting revenue around $3.80 billion, adjusted EBITDA at $667 million, and non-GAAP EPS of $4.72 to $4.77. The company raised its low-end free cash flow guidance to $350 million to $360 million, reflecting optimism in cash generation amid financial optimization. Looking ahead to 2027, BWXT anticipates high-single-digit revenue growth, with government operations expanding at a high-single to low-double-digit rate and commercial operations experiencing low-single-digit growth, partly offset by a planned medical business divestiture. Managerial projections indicate a high-single to low-double-digit growth in adjusted EBITDA and non-GAAP EPS, alongside relatively flat free cash flow.",
  "summary": null,
  "key_points": [
    "BWXT reported Q3 2026 earnings with adjusted earnings exceeding expectations",
    "Revenue fell 1.8% below consensus estimate at $953 million",
    "Free cash flow increased 59% to $151 million"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}